Amphastar Pharmaceuticals (AMPH) Cash & Current Investments (2013 - 2026)

Amphastar Pharmaceuticals has reported Cash & Current Investments for 14 years, with the latest figure at $290.1 million in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 25.19% year-over-year to $290.1 million in Q2 2026; TTM through Jun 2026 was $290.1 million, a 25.19% increase from a year earlier, with the FY2025 full-year figure at $282.8 million, up 27.6% from the prior year.
• Cash & Current Investments was $290.1 million for Q2 2026 at Amphastar Pharmaceuticals, down from $292.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $299.9 million in Q3 2023, with the low at $163.1 million in Q2 2023.
• Average Cash & Current Investments over 5 years is $235.1 million, with a median of $234.3 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments soared 62.9% in 2023, then fell 18.19% in 2025.
• Over 5 years, Cash & Current Investments stood at $175.8 million in 2022, then surged by 46.11% to $256.8 million in 2023, then declined by 13.69% to $221.6 million in 2024, then rose by 27.6% to $282.8 million in 2025, then climbed by 2.59% to $290.1 million in 2026.
• The last three Cash & Current Investments figures came in at $290.1 million (Q2 2026), $292.0 million (Q1 2026), and $282.8 million (Q4 2025), per Business Quant data.